What is the initial Guideline-Directed Medical Therapy (GDMT) for heart failure?

Guideline-Directed Medical Therapy (GDMT) for Heart Failure

Initial GDMT for Heart Failure with Reduced Ejection Fraction (HFrEF)

All patients with HFrEF should be initiated on quadruple therapy consisting of four foundational medication classes: SGLT2 inhibitors, mineralocorticoid receptor antagonists (MRAs), beta-blockers, and renin-angiotensin system (RAS) inhibitors (preferably ARNI), as this combination reduces mortality risk by approximately 73% over 2 years compared to no treatment. 1

The Four Pillars of GDMT for HFrEF

1. SGLT2 Inhibitors (Dapagliflozin or Empagliflozin)

• Start immediately as they have minimal blood pressure effects and require no dose titration 1, 2
• Effective even with moderate kidney dysfunction (CKD stage 4) 3
• Provide rapid symptom benefits and mortality reduction 1

2. Mineralocorticoid Receptor Antagonists (Spironolactone or Eplerenone)

• Initiate at low doses: spironolactone 12.5-25 mg daily or eplerenone 25 mg daily 1
• Provide at least 20% mortality reduction 1
• Monitor potassium and creatinine closely, especially when combined with RAS inhibitors 1, 2

3. Beta-Blockers (Carvedilol, Metoprolol Succinate, or Bisoprolol)

• Start at low doses if heart rate >70 bpm 2
• Provide at least 20% mortality reduction 1
• Uptitrate gradually to target doses shown effective in trials 4, 1

4. RAS Inhibitors

• Preferred: ARNI (Sacubitril/Valsartan) - reduces mortality by at least 20% (superior to ACE inhibitors/ARBs) 1
• Alternative: ACE inhibitors or ARBs - reduce mortality by 5-16% 1
• Start at low doses with careful blood pressure monitoring 2
• Consider ARNI as first-line for NYHA class II-III symptoms 2

Implementation Strategy: Rapid Initiation Approach

Start all four medication classes simultaneously or in rapid sequence rather than traditional step-by-step titration, as clinical inertia with sequential approaches leads to suboptimal implementation. 2

Sequencing for optimal tolerability:

1. Week 1: Initiate SGLT2 inhibitor + low-dose MRA (minimal BP impact) 2
2. Week 1-2: Add low-dose beta-blocker if heart rate >70 bpm 2
3. Week 2-3: Add low-dose ARNI or ACE inhibitor/ARB 2
4. Weeks 3-8: Uptitrate each medication every 1-2 weeks to target doses 1

Critical Implementation Points

In-Hospital Initiation

• Initiate GDMT during hospitalization for heart failure, as deferring therapy results in patients never receiving treatment 2
• Continue GDMT in hospitalized patients except when hemodynamically unstable or contraindicated 4
• Rapid, high-intensity uptitration within 2 weeks of discharge (STRONG-HF approach) reduces mortality and HF readmissions by 34% at 180 days 2

Monitoring During Uptitration

• Check blood pressure, heart rate, renal function, and electrolytes 1-2 weeks after each dose increment 1, 2
• Accept modest creatinine increases up to 30% above baseline without discontinuing RAS inhibitors 1
• Asymptomatic vital sign changes should not prevent uptitration 1
• More frequent monitoring needed in elderly patients and those with chronic kidney disease 4

Target Dosing

• Achieving target doses provides the greatest mortality benefit, yet only 1% of patients receive all medications at target doses 1
• Transitioning from traditional dual therapy (ACE inhibitor + beta-blocker) to quadruple therapy extends life expectancy by approximately 6 years 1

Special Populations

Low Blood Pressure (<90 mmHg systolic)

• Prioritize SGLT2 inhibitors and MRAs first (minimal BP effect) 1
• Use selective β₁ receptor blockers 1
• Start with very low-dose ARNI or low-dose ACE inhibitor/ARB 1
• Small incremental dose increases with close monitoring 1
• Excessive focus on blood pressure alone is insufficient; comprehensive clinical assessment is crucial 2

End-Stage CKD

• SGLT2 inhibitors remain most strongly recommended, safe through CKD stage 4 3
• Consider hydralazine-isosorbide dinitrate combination if RAS inhibitors not tolerated, particularly in African American patients 3
• Higher doses or combination diuretic therapy may be needed 3

Improved Ejection Fraction

• Continue full HFrEF regimen even if EF improves to >40%, as discontinuation leads to clinical deterioration 1

Diuretic Management

Loop diuretics should be added only for volume overload symptoms, as they provide no mortality benefit 3

• Initial IV dose should equal or exceed chronic oral daily dose 4
• Titrate based on urine output and congestion symptoms 4
• Consider adding thiazide for diuretic resistance 4

---

Initial GDMT for Heart Failure with Preserved Ejection Fraction (HFpEF)

SGLT2 inhibitors (dapagliflozin or empagliflozin) are the strongest evidence-based therapy for HFpEF (Class 2a recommendation), reducing HF hospitalizations and cardiovascular death based on DELIVER and EMPEROR-PRESERVED trials. 1

Core HFpEF Management

1. SGLT2 Inhibitors - Strongest recommendation (Class 2a) 1

2. Blood Pressure Control - Class I recommendation, cornerstone of HFpEF management 1

3. Mineralocorticoid Receptor Antagonists - Weaker recommendation (Class 2b) based on TOPCAT trial showing reduction in HF hospitalizations 1

4. Atrial Fibrillation Management - Class 2a recommendation for symptom control 1

5. Phenotype-Directed Approach - Focus on comorbidity management including hypertension, diabetes, obesity, and atrial fibrillation 1

Key Difference from HFrEF

• HFpEF therapies primarily reduce hospitalizations rather than mortality 1
• No established mortality benefit from the four-pillar approach used in HFrEF 1

---

Common Pitfalls to Avoid

1. Clinical Inertia: Waiting to optimize one medication before starting the next delays life-saving therapy 2

2. Premature Discontinuation: Temporary symptoms of fatigue and weakness with dose increases usually resolve within days; reassure patients rather than stopping therapy 4

3. Overreacting to Laboratory Changes: Modest creatinine elevation (up to 30% above baseline) is acceptable and expected 1

4. Deferring Hospital Initiation: Patients who don't start GDMT during hospitalization often never receive it 2

5. Stopping Therapy After EF Improvement: Continue full HFrEF regimen even when EF recovers 1

6. Attributing Adverse Events to GDMT: Most adverse events in HF patients are not attributable to GDMT medications 1

7. Blood Pressure Fixation: Patients with adequate perfusion can tolerate systolic BP 80-100 mmHg; comprehensive assessment matters more than BP alone 4, 2